Cambrex Invests $120 Million to Enhance API Manufacturing in the U.S.

Cambrex, a renowned global CDMO, has announced a substantial $120 million investment aimed at expanding its U.S. operations. This strategic move is set to address the growing demand for API development and manufacturing, with a particular focus on bolstering the peptide therapeutics market.

According to Cambrex CEO Thomas Loewald, this investment is crucial for enhancing supply chain security and resilience as drug manufacturing reshoring efforts intensify in partnership with federal and state agencies. The Charles City, Iowa site will see a significant 40% increase in its manufacturing capacity, approaching one million liters.

This investment underscores Cambrex's ongoing commitment to pharmaceutical manufacturing stability in the U.S., building on previous expansions in Iowa, North Carolina, and Massachusetts over the recent years.